bluebird bio's GAAP loss for 9 months of 2023 was $123.3 million, down 2.5 times from $298.8 million in the prior year. Revenue increased 6-fold to $21.663 mln vs. $3.534 mln a year earlier.
bluebird bio's GAAP loss for 9 months of 2023 was $123.3 million, down 2.5 times from $298.8 million in the prior year. Revenue increased 6-fold to $21.663 mln vs. $3.534 mln a year earlier. 
investor.bluebirdbio.com
English (US) 